What zanzalintinib is
Zanzalintinib is an oral tyrosine kinase inhibitor developed by Exelixis. Tyrosine kinases are enzymes that relay growth signals inside cells, and the STELLAR-303 investigators describe zanzalintinib as a multitargeted inhibitor of them. In colorectal cancer it is being developed in combination with atezolizumab, an immunotherapy that blocks PD-L1.
Clinical evidence: STELLAR-303
STELLAR-303 randomized 901 patients with refractory metastatic colorectal cancer, whose disease had progressed after standard chemotherapies, to zanzalintinib plus atezolizumab or to regorafenib, an existing oral option. Results were published in The Lancet in 2025:
| Measure | Zanzalintinib + atezolizumab | Regorafenib |
|---|---|---|
| Median overall survival (all patients) | 10.9 months | 9.4 months |
| Overall survival hazard ratio (all patients) | 0.80 (p = 0.0045) | |
| Overall survival hazard ratio (no liver metastases, interim) | 0.79 (p = 0.087, not significant) | |
| Grade 3 or worse treatment-related adverse events | 60% | 37% |
The trial met its primary goal in the full population: a 20% reduction in the risk of death. The absolute gain in median survival was about six weeks, and serious side effects were notably more common.
Regulatory status
Exelixis submitted a New Drug Application in December 2025 for patients whose metastatic colorectal cancer had progressed after fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (and, for RAS wild-type tumors, an anti-EGFR therapy). The FDA accepted it under standard review with a December 3, 2026 target date (company-reported).
On September 10, 2026, Exelixis disclosed that the FDA had extended the review by three months, to March 3, 2027. The company had submitted updated safety and efficacy data in response to an FDA request, and the FDA deemed it a major amendment (company-reported, Form 8-K).
Scientific perspective
STELLAR-303 is a useful case study in statistical versus clinical significance. The survival benefit is statistically robust in the full population, but modest in absolute terms, comes with more toxicity, and was not significant in a prespecified subgroup. Regulators approve drugs on the balance of benefit and risk, so a modest benefit in a setting with few options can still support approval. See What Is Statistical Significance in Clinical Trials?
Development perspective
- Next milestone: the FDA decision, due March 3, 2027. A review extension after a major amendment is a procedural step, not a rejection. Historically, about 90.6% of applications that reach the FDA are eventually approved; that is an industry average, not a prediction.
- Pipeline: Phase 3 programs in kidney cancer (including STELLAR-304) and neuroendocrine tumors could extend the drug beyond colorectal cancer.
- Company context: Exelixis describes zanzalintinib as its lead clinical asset (Form 10-Q).
Development timeline
- Sep 7, 2022STELLAR-303 begins randomizing patients. Peer-reviewed
- Oct 20, 2025STELLAR-303 published: overall survival 10.9 vs 9.4 months with regorafenib (HR 0.80). Peer-reviewed
- Dec 2025Exelixis submits a New Drug Application for zanzalintinib plus atezolizumab in metastatic colorectal cancer. Company-reported
- Jan 2026FDA accepts the application under standard review, with a December 3, 2026 target date. Company-reported
- Sep 10, 2026FDA extends the review by three months to March 3, 2027 after deeming updated data a major amendment. Company-reported
What could change the outlook
- The FDA decision, now due March 3, 2027 (company-reported).
- How the FDA weighs the modest survival gain against higher toxicity, and the non-significant result in patients without liver metastases.
- Kidney cancer Phase 3 results, including STELLAR-304, whose primary completion the registry estimates for December 2026.
- STELLAR-316, a Phase 3 colorectal cancer trial run with Natera and Merck (company-reported).
Latest company disclosures
Company press releases (SEC filings and PR Newswire) that mention Zanzalintinib. Company-reported, not independently verified.
- Quarterly reportCompany-reportedOct 29, 2026
Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
“Exelixis continued to execute across all of our key priorities in the third quarter, driving the cabozantinib franchise forward while preparing for zanzalintinib as our next potential franchise opportunity,” said Michael M.
- RegulatoryCompany-reportedSep 11, 2026
Today, Exelixis, Inc. (Exelixis) announced that on September 10, 2026, the U.S. Food and Drug Administration (FDA) notified Exelixis that it had extended the review period for Exelixis’ new drug application (NDA) for...
zanzalintinib, in combination with atezolizumab, for the treatment of patients with metastatic colorectal cancer by three months.
- Quarterly reportCompany-reportedAug 5, 2026
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
“For zanzalintinib, our next potential franchise molecule, the R&D organization is executing on our priority goals for pivotal data readouts, clinical trial enrollment and new study initiations, while also laying the foundation for the next wave of development opportunities.